{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:36:29Z","timestamp":1791329789995,"version":"4.3.1"},"reference-count":67,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is an unprecedented time for the treatment of patients with chronic lymphocytic leukemia (CLL) with the recent approval of several targeted agents for use in frontline, relapsed, refractory, and high-risk disease. Traditionally, frontline management of CLL has been a combination of chemotherapy (fludarabine, cyclophosphamide, bendamustine, or chlorambucil) with an anti-CD20 monoclonal antibody (rituximab, ofatumumab, obinutuzumab). The current landscape is rapidly evolving with the advent of therapies that demonstrate selective inhibition of important pathways necessary for CLL proliferation and survival. Despite considerable progress, much is still unknown and optimal treatment selection and sequence is still debatable. None of the new agents have been compared against each other and the impact of adding an additional agent to monotherapy is not yet fully elucidated. In routine clinical practice, the choice of therapy is based on nonrandomized comparisons, presence of comorbidities, and toxicity considerations. These recently approved drugs (ibrutinib, idelalisib, and venetoclax) are reporting excellent outcomes, including patients with high-risk disease such as 17p deletion (17p\u2212) or TP53 mutations (TP53mut). Ibrutinib and venetoclax have been approved for use in 17p\u2212 patients (frontline and relapsed, respectively). Ibrutinib is currently moving into the frontline space given recent regulatory approvals. This review will summarize and interpret the limited therapeutic sequencing data available, highlighting the need for additional studies to optimize combination strategies and treatments after failure or discontinuation of these novel agents.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.128","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Sequencing of chronic lymphocytic leukemia therapies"],"prefix":"10.1182","volume":"2016","author":[{"given":"Jacqueline C.","family":"Barrientos","sequence":"first","affiliation":[{"name":"CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School of Medicine, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111707362556100_B1","unstructured":"American Cancer Society. Cancer facts and figures 2016. http:\/\/www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc-047079.pdf. Accessed 1 August 2016."},{"issue":"1","key":"2019111707362556100_B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2019111707362556100_B3","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111707362556100_B4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111707362556100_B5","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111707362556100_B6","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.2174\/138161212801227078","article-title":"Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy","volume":"18","author":"Dal Bo","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"16","key":"2019111707362556100_B7","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111707362556100_B8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Kharfan-Dabaja","year":"2012","journal-title":"Cancer Contr"},{"issue":"31","key":"2019111707362556100_B9","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111707362556100_B10","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111707362556100_B11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am J Hematol"},{"issue":"21","key":"2019111707362556100_B12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood.V122.21.524.524","article-title":"Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia\u2014first results of a randomized German-French cooperative phase III trial","volume":"122","author":"Schweighofer","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111707362556100_B13","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","article-title":"Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL","volume":"123","author":"Geisler","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111707362556100_B14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"issue":"31","key":"2019111707362556100_B15","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111707362556100_B16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111707362556100_B17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111707362556100_B18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/leu.2008.260","article-title":"A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease","volume":"23","author":"Best","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111707362556100_B19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/gcc.20794","article-title":"Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters","volume":"49","author":"Haferlach","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"2019111707362556100_B20","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"issue":"26","key":"2019111707362556100_B21","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"7574","key":"2019111707362556100_B22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2019111707362556100_B23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2014.10.024","article-title":"Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation","volume":"21","author":"Cassaday","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111707362556100_B24","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Stilgenbauer","year":"2010"},{"issue":"11","key":"2019111707362556100_B25","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111707362556100_B26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"2019111707362556100_B27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"2019111707362556100_B28","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3109\/10428194.2013.796050","article-title":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group","volume":"54","author":"Cramer","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"2019111707362556100_B29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111707362556100_B30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111707362556100_B31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"2019111707362556100_B32","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume-title":"Lancet Oncol","author":"Eichhorst","year":"2016"},{"key":"2019111707362556100_B33","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdn460","article-title":"Chronic lymphocytic leukaemia: a short overview","volume":"19","author":"Montserrat","year":"2008","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111707362556100_B34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"issue":"16","key":"2019111707362556100_B35","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111707362556100_B36","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","article-title":"Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study","volume":"32","author":"Hillmen","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111707362556100_B37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Fo\u00e0","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111707362556100_B38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2040620712445329","article-title":"Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia","volume":"3","author":"Dyer","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"9980","key":"2019111707362556100_B39","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"22","key":"2019111707362556100_B40","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111707362556100_B41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111707362556100_B42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111707362556100_B43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111707362556100_B44","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111707362556100_B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.833.833","volume":"126","author":"Stilgenbauer","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111707362556100_B46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111707362556100_B47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111707362556100_B48","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111707362556100_B49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2019111707362556100_B50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111707362556100_B51","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111707362556100_B52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111707362556100_B53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111707362556100_B54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.330.330","article-title":"Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111707362556100_B55","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111707362556100_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111707362556100_B57","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"issue":"35","key":"2019111707362556100_B58","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111707362556100_B59","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","article-title":"Risk categories and refractory CLL in the era of chemoimmunotherapy","volume":"119","author":"Zenz","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"2019111707362556100_B60","article-title":"Outcomes with ibrutinib by line of therapy in patients with CLL: analyses from phase III data","volume":"34","author":"O\u2019Brien","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111707362556100_B61","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111707362556100_B62","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111707362556100_B63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"23","key":"2019111707362556100_B64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.719.719","article-title":"Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study","volume":"126","author":"Mato","year":"2015","journal-title":"Blood"},{"issue":"suppl","key":"2019111707362556100_B65","article-title":"Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib","volume":"34","author":"Jones","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111707362556100_B66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3345.3345","article-title":"Preliminary safety results from the phase IIIb GREEN study of obinutuzumab (GA101) alone or in combination with chemotherapy for previously untreated or relapsed\/refractory chronic lymphocytic leukemia (CLL)","volume":"124","author":"Bosch","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111707362556100_B67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.830.830","article-title":"Deep and durable responses following venetoclax (ABT-199\/GDC-0199) combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from a phase 1b study","volume":"126","author":"Ma","year":"2015","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/128\/1250413\/hem088360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/128\/1250413\/hem088360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T23:47:13Z","timestamp":1718927233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/128\/21035\/Sequencing-of-chronic-lymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.128","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}